One-month online access to a database for therapeutics and therapy candidates targeting PSMA (prerequisite: access to internet). In addition to androgen deprivation therapy (ADT), there have been ...

The antibody 7E11 binds to the intracellular epitope of PSMA and can reach this only when the cell membrane is damaged. In this case, the tumor on the right was irradiated; the left one was not. The ...

But if you've already been diagnosed with prostate cancer, you may need a different test-- for the prostate-specific membrane antigen or PSMA. PSA can show up in cells throughout the body ...

For JANX007, that antigen is prostate-specific membrane antigen (PSMA), which ... one that has not been processed by the tumor), the plasma levels of the activated form are exponentially lower ...

Pluvicto™ (formerly 177Lu-PSMA-617) is a radioligand therapy that was approved by the FDA in March 2022 to treat progressive, PSMA positive metastatic castration-resistant prostate cancer. Pluvicto™ ...

PSMA-targeted radioligand therapies (PRLT) for metastatic castration-resistant prostate cancer (mCRPC) decrease PSA levels and improve quality of life (QoL) with infrequent severe toxic events ...

In the PSMAfore trial, Pluvicto reduced the risk of radiographic progression or death by 59%. The Food and Drug Administration (FDA) has expanded the approval of Pluvicto ® (lutetium Lu 177 ...

The drug is intended for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have received one round of androgen receptor pathway inhibitors (ARPIs), a class of ...

The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK said it has given a world-first approval to Rotop's trofolastat, a PSMA-targeting agent for detecting lesions in men with ...

68 Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177 Lu-PSMA617 in 8 patients with PSA decline ? 98 percent in a prospective phase II study. Any disease ...

Prostate Cancer Risk Increases By 45% Among Men Who Share One Troubling Behavior The drug is intended for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC ...